Company intelligence / Profile preview

BridgeBio Pharma

Palo Alto, California, United Statesbridgebio.com ↗

Ownership: Public · BBIO
Development stage: Commercial

Overview

BridgeBio has multiple programs in development, with acoramidis for ATTR cardiomyopathy as a key focus for launch in 2024. The company has positive Phase 1 data for BBP-711 for PH1, and infigratinib received Breakthrough Therapy Designation for achondroplasia. The company recently launched BridgeBio Oncology Therapeutics (BBOT) with $200M in external capital to advance its precision oncology pipeline.

Therapeutic areas: CardiovascularNephrologyEndocrinologyOncologyRare DiseasesNeurology
Modalities: Small moleculesGene therapyAAV gene therapy
Industry: Biotech

Drug pipeline

22 assets

acoramidis

Approved

21 more assets in the full pipeline.

Request access →

Financials

Market cap: $14.6B
Total revenue: $222.4M
Enterprise value: $16.4B

Beyond the preview

Go deeper on BridgeBio Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BridgeBio Pharma.

Explore the full profile